Department of Ophthalmology, Saneikai Tsukazaki Hospital, Himeji, Hyogo, Japan.
Department of Ophthalmology, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan.
Sci Rep. 2020 Nov 12;10(1):19667. doi: 10.1038/s41598-020-76840-6.
Here, we examined prognostic factors for extremely poor visual outcomes in patients with central retinal vein occlusion (CRVO) in actual practices. We included 150 consecutive eyes with treatment-naïve acute CRVO from four different facilities and observed them for over 24 months. Macular edema (ME) was treated with one or three monthly anti-vascular endothelial growth factor injections (1 or 3 + pro re nata). According to the final Snellen visual acuity (VA), we divided the patients into very poor VA (< 20/200) and control (≥ 20/200) groups and examined risk factors for poor final visual outcomes. The baseline Snellen VA was hand motion to 20/13. The mean number of anti-VEGF injections for ME was 5.3 ± 3.7 during the follow-up period. In total, 49 (32.7%) patients exhibited a very poor final VA; this group comprised significantly older patients with a significantly poorer baseline VA (P < 0.01 for both) than the control group. Comorbid internal carotid artery disease and diabetic retinopathy were significantly associated with a poor final VA. In actual clinical practice, visual outcomes may be extremely poor despite ME treatment in certain patients with CRVO, with advanced age, poor baseline VA, and comorbid internal carotid artery disease and diabetic retinopathy being significant risk factors.
在这里,我们研究了在实际治疗中,视网膜中央静脉阻塞(CRVO)患者视力极差的预后因素。我们纳入了来自四个不同医疗机构的 150 只未经治疗的急性 CRVO 连续眼,并对其进行了超过 24 个月的观察。黄斑水肿(ME)采用每月一次或三次抗血管内皮生长因子注射(1 或 3+pro re nata)进行治疗。根据最终的 Snellen 视力(VA),我们将患者分为视力极差(<20/200)和对照组(≥20/200),并检查了导致视力预后不良的风险因素。基线 Snellen VA 为手动视力至 20/13。在随访期间,ME 的平均抗 VEGF 注射次数为 5.3±3.7。共有 49 名(32.7%)患者最终视力极差;与对照组相比,该组患者年龄明显较大,基线 VA 明显较差(两者均 P<0.01)。合并颈内动脉疾病和糖尿病性视网膜病变与最终视力不良显著相关。在实际临床实践中,尽管对 CRVO 患者的 ME 进行了治疗,但某些患者的视力结果可能极差,其显著风险因素为年龄较大、基线 VA 较差以及合并颈内动脉疾病和糖尿病性视网膜病变。